Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study
Izanne Roos(The Royal Melbourne Hospital), Marzena Fabis-Pedrini(The University of Western Australia), Sifat Sharmin(The Royal Melbourne Hospital), Beatriz Romero-Ferrando(Waikato Hospital), Radek Ampapa(Hospital Jihlava), Julie Prévost(Cegep de Saint Jerome), Alasdair Coles(University of Cambridge), Sara Eichau Madueño(Hospital Universitario Virgen Macarena), Miroslav Mareš(Pardubice Region), Marek Peterka(Charles University), Emanuele D’Amico(University of Catania), Jana Libertínová(Charles University), Jana Houskova(Nemocnice České Budějovice), Simón Cárdenas-Robledo(Hospital Universitario Nacional de Colombia), Suzanne Hodgkinson(Liverpool Hospital), Barbara Willekens(University of Antwerp), Nevin John(Monash Health), Vincent Van Pesch(Cliniques Universitaires Saint-Luc), Allan G Kermode(Murdoch University), Yolanda Blanco(University of Foggia), Raed Alroughani(Amiri Hospital), Dana Horakova(Charles University), Cavit Boz(Karadeniz Technical University), Helmut Butzkueven(Monash University), Eva Recmanova(UCLouvain), Oliver Gerlach(Maastricht University Medical Centre), Eva Kubala Havrdova(Charles University), Pamela A McCombe(The University of Queensland), Pavel Stourac(Masaryk University), Pavel Hradilek(University Hospital Ostrava), Guy Laureys(Ospedale Garibaldi), Cristina Ramo-Tello(Hospital Universitari Germans Trias i Pujol), Marc Girard(Hôpital Notre-Dame), J William L Brown(University of Cambridge), Vahid Shaygannejad(Isfahan University of Medical Sciences), Davide Maimone(Ospedale Garibaldi), Richard Macdonell(The University of Queensland), Jose E Meca-Lallana(Hospital Universitario Virgen de la Arrixaca), Anneke van der Walt(Monash University), Matteo Foschi(University of L'Aquila), Saloua Mrabet(Tunis University), Elisabetta Cartechini(University of Macerata), Alexandre Prat(Hôpital Notre-Dame), Murat Terzi(Ondokuz Mayıs University), Olga Skibina(Box Hill Hospital), Marta Vachova(Charles University), Samia Joseph Khoury(American University of Beirut), Zbyšek Pavelek, Katherine Buzzard(Box Hill Hospital), Zuzana Rous(University Hospital Olomouc)
Cited by 0
Related Papers
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
|Journal of Clinical Investigation|2009|299
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
|The Lancet Neurology|2021|192
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
|The Lancet Neurology|2019|188